A Licensed Combined Haemophilus Influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine

<p><b>Article full text</b></p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s40121-013-0007-5"><b>here</b>.</a></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p> </p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p> <p> </p> <p> </p> <p> </p> <p> </p

Additional file 2: of Who’s holding the baby? A prospective diary study of the contact patterns of mothers with an infant

Supplementary Figure 1. Location types visited by participants, for weekend days only. (DOCX 74 kb

Additional file 1 of Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context

Model description and additional results tables. This document presents the model equations, the distributions from which the model parameters were sampled, and tables of simulation results for each pandemic scenario and for each targeted NAI strategy. (PDF 103 kb

Additional file 5: of Who’s holding the baby? A prospective diary study of the contact patterns of mothers with an infant

Supplementary Figure 2. Age distribution of unique non-companion contacts. (DOCX 30 kb

Timeline of major vaccination and reporting changes in Australia from 1953 to present.

<p>The timeline covers the commencement of vaccination in 1953 through various schedule changes, the introduction of mandatory notification and changes to the vaccine type used in Australia.</p

Cross-sectional distribution of anti-PT IgG levels.

<p>Distributions are shown by age (1–4 years) and age group (≥5 years). A. 1997/98; B. 2002; and C. 2007.</p

Australian age specific population prevalence, expressed in percentages, for Undetectable (<5 EU/ml) and High (≥62.5 EU/ml) antibody categories, with 95% Clopper-Pearson confidence intervals shown in brackets.

*<p>significantly lower than previous collection.</p>†<p>significantly higher than previous collection.</p

Attack rates for targeted vaccination in Scenario C.

<p>Epidemic attack rates for targeted distribution of a vaccine stockpile sufficient for 50 per cent coverage. For all epidemics the initial effective reproduction number in the absence of vaccination is fixed at 2. The axis labelled “exp coverage” denotes coverage in the experienced population and <i>ϵ</i>_v is the relative infectiousness of vaccinated and unvaccinated naïve hosts. The minimum plotted value of “exp coverage” indicates full coverage in the naïve population with the remainder given to experienced hosts, the maximum plotted value is for a scenario in which all vaccines are given to experienced hosts, and a value of 0.5 indicates equal coverage in naïve and experienced hosts (<i>i.e.</i> general population distribution). Panels represent estimates for different pre-pandemic immunity and vaccine action scenarios; 80 per cent of the population with naturally acquired CTL-mediated immunity (<i>f</i>_<i>E</i> = 0.8) and saturating vaccine action (scenario B), the same population with a vaccine that boosts protection in all hosts (scenario C), a population in which 50 per cent of those with naturally acquired CTL responses also have protective antibody to the pandemic strain and vaccine action is again boosting (scenario D). The strength of naturally acquired CTL-mediated immunity is set to <i>ϵ</i> = 0.5.</p

Disease transmission and clinical pathways models

This repository contains the disease transmission and clinical pathways models used in our modelling study, "Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context", and is distributed under the terms of the GNU General Public License (version 3 or any later version).<br

Model structure.

<p>Susceptible hosts are divided into 4 strata (labelled by <i>i</i>) depending on their prior influenza experience and vaccination status. Susceptible hosts <i>S</i>_<i>i</i> become exposed (<i>E</i>_<i>i</i>) at a rate proportional to <i>β</i>_<i>f</i>, become infectious (<i>I</i>_<i>i</i>) with Erlang distributed waiting time with rate parameter <i>γ</i> = 1/(1.3 days) and recover (<i>R</i>_<i>i</i>) at a rate <i>ν</i> = 1/(1.6 days). Dashed lines indicate the vaccination of hosts. Note we assume that vaccines do not alter the infectiousness of already exposed hosts (although this distinction is of little consequence if vaccination occurs very early in a pandemic). We allow for the possibility of strain-specific antibody to the pandemic strain by assuming that some (experienced) hosts begin in the recovered state <i>R</i>₃. We assume infected-acquired immunity is maintained over the course of the simulation, however in practice as immunity wanes recovered hosts who were originally naïve migrate to the appropriate <i>experienced</i> susceptible state (<i>R</i>₁ → <i>R</i>₄, <i>R</i>₂ → <i>R</i>₃).</p